Literature DB >> 16825199

The N-terminal domains of neuregulin 1 confer signal attenuation.

Carmen M Warren1, Kian Kani, Ralf Landgraf.   

Abstract

Degradation of activated ERBB receptors is an important mechanism for signal attenuation. However, compared with epidermal growth factor (EGF) receptor, the ERBB2/ERBB3 signaling pair is considered to be attenuation-deficient. The ERBB2/ERBB3 ligands of the neuregulin family rely on an EGF-like domain for signaling and are generated from larger membrane-bound precursors. In contrast to EGF, which is processed to yield a 6-kDa peptide ligand, mature neuregulins retain a variety of segments N-terminal to the EGF-like domain. Here we evaluate the role of the N-terminal domain of neuregulin 1 in signaling and turnover of ERBB2/ERBB3. Our data suggest that whereas the EGF-like domain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation. This manifests itself for both ERBB2 and ERBB3 but is more pronounced and coupled directly to degradation for ERBB3. When stimulated with only the EGF-like domain, ERBB3 shows degradation rates comparable with constitutive turnover, but stimulation with full-length neuregulin 1 resulted in receptor degradation at rates that are comparable with activated EGF receptor. Most of the enhancement in down-regulation was maintained after replacing the Ig-like domain with a thioredoxin protein of comparable size but different amino acid composition, suggesting that the physical presence but not specific properties of the Ig-like domain are needed. This sequence-independent effect of the N-terminal domain correlates with an enhanced ability of full-size neuregulin 1 to disrupt higher order oligomers of the ERBB3 extracellular domains in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825199     DOI: 10.1074/jbc.M512887200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale.

Authors:  Nirav Patel; Antoni Barrientos; Ralf Landgraf
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 2.  Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.

Authors:  Xiangyou Hu; Qingyuan Fan; Hailong Hou; Riqiang Yan
Journal:  J Neurochem       Date:  2015-11-13       Impact factor: 5.372

3.  Geldanamycin selectively targets the nascent form of ERBB3 for degradation.

Authors:  Candice S Gerbin; Ralf Landgraf
Journal:  Cell Stress Chaperones       Date:  2010-01-19       Impact factor: 3.667

4.  Cadm3 (Necl-1) interferes with the activation of the PI3 kinase/Akt signaling cascade and inhibits Schwann cell myelination in vitro.

Authors:  Ming-Shuo Chen; Hyosung Kim; Léonard Jagot-Lacoussiere; Patrice Maurel
Journal:  Glia       Date:  2016-09-23       Impact factor: 7.452

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers.

Authors:  Euisun Park; Rose Baron; Ralf Landgraf
Journal:  Biochemistry       Date:  2008-10-23       Impact factor: 3.162

7.  Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.

Authors:  Steven M Jay; Elma Kurtagic; Luis M Alvarez; Seymour de Picciotto; Edgar Sanchez; Jessica F Hawkins; Robin N Prince; Yadir Guerrero; Carolyn L Treasure; Richard T Lee; Linda G Griffith
Journal:  J Biol Chem       Date:  2011-05-26       Impact factor: 5.157

Review 8.  HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

Authors:  Ralf Landgraf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 9.  Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2.

Authors:  Riqiang Yan
Journal:  Front Mol Neurosci       Date:  2017-04-19       Impact factor: 5.639

10.  Association of NRG1 and AUTS2 genetic polymorphisms with Hirschsprung disease in a South Chinese population.

Authors:  Yan Zhang; Xiaoli Xie; Jixiao Zeng; Qiang Wu; Ruizhong Zhang; Deli Zhu; Huimin Xia
Journal:  J Cell Mol Med       Date:  2018-01-29       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.